Rib-X Pharmaceuticals, the New Haven, CT-based developer of antibiotics, has raised another $5.5 million in debt and options, according to a regulatory filing. The deal could be worth as much as $15 million over time. We last wrote about Rib-X in March, when Mark Leuchtenberger replaced Susan Froshauer as the company’s CEO. Rib-X, founded in 2000, had raised more than $158 million before the most recent shot of cash.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
